Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

AATS.16: Tricuspid regurgitation is rare following mitral valve repair

Older patients with atrial fibrillation are more likely to develop tricuspid regurgitation after isolated mitral valve repair for mitral regurgitation, according to a prospective study. However, after a mean follow-up period of 9.1 years, only approximately 3.3 percent of patients had tricuspid regurgitation.

AATS.16: Investigational aortic valve replacement system is safe and effective at 1 year

After one year, 96 percent of patients with severe aortic stenosis who were implanted with the investigational Intuity aortic valve replacement system had survived, according to a prospective, nonrandomized, multicenter trial.

Thumbnail

[VIDEO] Building a Protected PCI Program: Defining Algorithms, Selecting Patients

Offered in cooperation with Abiomed

Good outcomes in revascularizing high-risk, complex PCI patients start with careful patient selection. The heart team at VA North Texas Healthcare System in Dallas shares their decision-making process for patient selection for Protected PCI.

Drug-coated balloons compare favorably with uncoated balloons or drug-eluting stents for revascularization of infrapopliteal arteries

A meta-analysis of randomized trials found that treating infrapopliteal arteries with drug-coated balloons was associated with similar clinical outcomes and favorable angiographic efficacy compared with using uncoated balloons or drug-eluting stents.

Thumbnail

Robotically assisted PCI with the CorPath system is safe and feasible

Researchers found the clinical success rates were above 99 percent and similar in patients undergoing robotically assisted PCI or manual PCI.

Trial examines Watchman device in patients ineligible for oral anticoagulation

Patients with atrial fibrillation who are ineligible for oral anticoagulation had 75 percent fewer ischemic strokes and system embolisms if they received the Watchman left atrial appendage occlusion device than if they received aspirin alone.

Corindus Vascular Robotics increases revenue in first quarter

During the first quarter of 2016, Corindus Vascular Robotics, Inc. increased its revenue to $1.1 million, up from $800,000 in the same period last year. The company also installed two new CorPath systems during the quarter, increasing the installed base to 40 systems, including 37 in the U.S. and three internationally.

SCAI.16: Men and women have similar short-term outcomes following TAVR

Men and women who underwent transcatheter aortic valve replacement (TAVR) had similar rates of survival, major adverse cardiovascular events and vascular complications at 30 days, according to a randomized trial.

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.